SOURCE: Streetwise Reports

Streetwise Reports

February 02, 2016 09:00 ET

DURECT Corp.'s CEO James E. Brown Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - February 02, 2016) - Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp. (NASDAQ: DRRX), which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report, DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech.

The Life Sciences Report:  Jim, you helped found DURECT Corp. back in 1998. It was spun out of Alza Corp. (acquired by Johnson & Johnson in 2001), a pioneer in the field of drug delivery formulations. You went public in 2000, and have endured a lot of market cycles through the years. As we speak, the capital markets are in the throes of global volatility resulting from a confluence of factors including the disturbing selloff in China, North Korea detonating an atomic bomb, diplomatic unrest between Saudi Arabia and Iran, and the U.S. Federal Reserve signaling it will continue to raise short-term interest rates. What have you learned about holding a business together during this kind of disruption?

JB: My experience in biopharma tells me that a company like DURECT is somewhat divorced from the hiccups occurring in China or in the broader economy. I'm not focused on anything but moving our pipeline along and bringing meaningful new drugs to the marketplace. If we do that successfully, then we're going to be successful for both shareholders and patients. In 2016 we have the potential to see our very first product come to market. This turmoil is a tough way to start the new year, for sure, but the U.S. and European economies seem to be in good shape.

Once things settle down, as they always do, it seems to me investors will come to realize that our sector, biopharmaceuticals, is a wonderful place to invest. This sector is the place to be because...

Continue reading this interview: Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown

About Streetwise Reports -  The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

DURECT Corp. is a sponsor of Streetwise Reports. Dr. James E. Brown had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Brown and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information